JP2015511625A - 呼吸器における急性炎症の治療 - Google Patents

呼吸器における急性炎症の治療 Download PDF

Info

Publication number
JP2015511625A
JP2015511625A JP2015502438A JP2015502438A JP2015511625A JP 2015511625 A JP2015511625 A JP 2015511625A JP 2015502438 A JP2015502438 A JP 2015502438A JP 2015502438 A JP2015502438 A JP 2015502438A JP 2015511625 A JP2015511625 A JP 2015511625A
Authority
JP
Japan
Prior art keywords
ccl7
antagonist
par
antagonists
ccl2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511625A5 (https=
Inventor
レイチェル チェンバース
レイチェル チェンバース
ポール マーサー
ポール マーサー
アンドリュー ウィリアムズ
アンドリュー ウィリアムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Biomedica PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Biomedica PLC filed Critical UCL Biomedica PLC
Publication of JP2015511625A publication Critical patent/JP2015511625A/ja
Publication of JP2015511625A5 publication Critical patent/JP2015511625A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015502438A 2012-03-30 2013-03-15 呼吸器における急性炎症の治療 Pending JP2015511625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1205739.4 2012-03-30
GBGB1205739.4A GB201205739D0 (en) 2012-03-30 2012-03-30 Treatment of acute inflammation in the respiratory tract
PCT/GB2013/050665 WO2013144563A1 (en) 2012-03-30 2013-03-15 Treatment of acute inflammation in the respiratory tract

Publications (2)

Publication Number Publication Date
JP2015511625A true JP2015511625A (ja) 2015-04-20
JP2015511625A5 JP2015511625A5 (https=) 2016-05-12

Family

ID=46160077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502438A Pending JP2015511625A (ja) 2012-03-30 2013-03-15 呼吸器における急性炎症の治療

Country Status (5)

Country Link
US (1) US20150079105A1 (https=)
EP (1) EP2830657A1 (https=)
JP (1) JP2015511625A (https=)
GB (1) GB201205739D0 (https=)
WO (1) WO2013144563A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018070605A (ja) * 2016-10-21 2018-05-10 国立大学法人山口大学 ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
WO2020227430A1 (en) 2019-05-07 2020-11-12 University Of Miami Treatment and detection of inherited neuropathies and associated disorders
CN114502164B (zh) * 2019-05-22 2024-01-26 石药集团中奇制药技术（石家庄）有限公司 杂环化合物及其盐的应用
EP4125909A1 (en) * 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
US20230165838A1 (en) * 2020-05-06 2023-06-01 Dimerix Bioscience Ltd. Treatment for acute respiratory distress syndrome
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
KR20250133491A (ko) * 2024-02-28 2025-09-08 재단법인 오송첨단의료산업진흥재단 인간 ccl7에 결합하는 신규한 항체 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
AU732820B2 (en) 1995-06-02 2001-05-03 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
EP1461300B1 (en) * 2001-11-30 2011-07-27 Biogen Idec MA Inc. Antibodies against monocyte chemotactic proteins
AU2003294290A1 (en) * 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2008016378A2 (en) * 2005-12-20 2008-02-07 Schering Corporation Methods to treat and/or prevent radiation- and/or chemical-induced toxicity in non-malignant tissue
US20140378502A1 (en) * 2011-05-12 2014-12-25 UNIVERSITé LAVAL Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AM J RESPIR CRIT CARE MED, vol. Vol.166, JPN6017000782, 2002, pages 268 - 273 *
AM J RESPIR CRIT CARE MED, vol. Vol.181, JPN6017000779, 2010, pages A2148 *
CHIN J EMERG MED, vol. 18, no. 12, JPN6017000781, 2009, pages 1278 - 1282 *
INTERNATIONAL IMMUNOPHARMACOLOGY, vol. Vol.10, JPN6017000783, 2010, pages 259 - 263 *
THE AMERICAN JOURNAL OF PATHOLOGY, vol. 179, no. 3, JPN6017000780, 2011, pages 1088 - 1094 *
THE JOURNAL OF IMMUNOLOGY, vol. Vol.168, JPN6017000778, 2002, pages 846 - 852 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018070605A (ja) * 2016-10-21 2018-05-10 国立大学法人山口大学 ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物

Also Published As

Publication number Publication date
GB201205739D0 (en) 2012-05-16
WO2013144563A1 (en) 2013-10-03
US20150079105A1 (en) 2015-03-19
EP2830657A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
JP2015511625A (ja) 呼吸器における急性炎症の治療
Matera et al. Prospects for COPD treatment
KR102666879B1 (ko) 항-tslp 항체를 이용한 천식의 치료
EP3506931B1 (en) Methods for preventing or treating allergy by administering an il-4r antagonist
Khameneh et al. C5a regulates IL-1β production and leukocyte recruitment in a murine model of monosodium urate crystal-induced peritonitis
Geng et al. Biologic therapies for allergic rhinitis and nasal polyposis
KR102512797B1 (ko) 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
TW201827079A (zh) 治療發炎症狀的方法
JP2017512193A (ja) Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法
JP2022515480A (ja) 掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体
TWI858221B (zh) 治療纖維化性疾病的相關靶點及其應用
RU2446825C2 (ru) Материалы и способы лечения хронических фиброзных заболеваний
US20130149312A1 (en) Compositions and methods for treating copd exacerbation
KR102558891B1 (ko) 항―ｉｌ４―ｉｌ１３ ２특이성 항체
KR20110128273A (ko) 골관절염 치료
JP2022547948A (ja) 片頭痛の処置のための併用療法
JP2010532334A (ja) 腎疾患を処置するための化合物および方法
US20030211103A1 (en) Use of primate IFN-gamma binding molecules
EP4103605A1 (en) Treatment of atopic dermatitis with anti-tslp antibody
AU2024289222A1 (en) Il-1ra blockers for treatment and prevention of sepsis
KR20240008231A (ko) 급성호흡곤란증후군의 치료 또는 예방 방법
Gauvreau et al. Inhaled Antisense for Treatment of Respiratory Disease
WO2021243396A1 (en) Therapeutic methods of using cd 14 antagonistic antibodies in treating conditions associated with a coronavirus infection including sars-cov-2 (covid-19)
TW202532439A (zh) 治療氣喘之方法
JP2020186187A (ja) 急性呼吸窮迫症候群の治療及び／又は予防剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180307